<?xml version='1.0' encoding='utf-8'?>
<document id="30351177"><sentence text="Comprehensive preclinical pharmacokinetic evaluations of trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, in cynomolgus monkeys." /><sentence text="Trastuzumab deruxtecan (DS-8201a) is an antibody-drug conjugate (ADC) composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2) conjugated to a topoisomerase I inhibitor (DXd) at a drug-to-antibody ratio (DAR) of 7-8" /><sentence text=" Here, we examined the pharmacokinetic (PK) profiles of DS-8201a and DXd in cynomolgus monkeys, a cross-reactive species" /><sentence text=" Following intravenous (iv) administration of DS-8201a, the linker was stable in plasma, and systemic DXd exposure was low" /><sentence text=" DXd was rapidly cleared following iv dosing" /><sentence text=" Biodistribution studies revealed that intact DS-8201a was present mostly in the blood without tissue-specific retention" /><sentence text=" The major pathway of excretion for DXd was the faecal route following iv administration of radiolabelled DS-8201a" /><sentence text=" The only detectable metabolite in the urine and faeces was unmetabolized DXd" /><sentence text=" DXd is a substrate of organic anion transporting polypeptides, P-gp, and breast cancer resistance protein" /><sentence text=" In conclusion, the stable linker in circulation and the high clearance of DXd upon release resulted in the low systemic exposure to DXd" /><sentence text=" Furthermore, the minimal tissue-specific retention and rapid excretion of DXd into faeces as its unmetabolized form with potentially limited impact on drug - drug interaction as a victim were also critical elements of the PK profile of DS-8201a" /><sentence text="" /></document>